NCT00402077 - A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects | Biotech Hunter

Enrollment

258

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

August 31, 2007

Study Completion Date

August 31, 2007

Conditions

OverweightObesity

Interventions

DRUG

pramlintide acetate

subcutaneous injection, three times a day, 120mcg

DRUG

sibutramine

oral tablet, once a day, 10mg

DRUG

phentermine

oral tablet, once a day, 37.5mg

DRUG

placebo

subcutaneous injection, three times a day

Trial Locations (16)

Research Site, Birmingham

Research Site, Phoenix

Research Site, Chula Vista

Research Site, La Jolla

Research Site, Los Angeles

Research Site, Walnut Creek

Research Site, Miami

Research Site, Pembroke Pines

Research Site, Louisville

Research Site, New York

Research Site, Raleigh

Research Site, Statesville

Research Site, Eugene

Research Site, Philadelphia

Research Site, Austin

Research Site, San Antonio